BLASTOID-DISCOVERY
Financiado
Human blastoids: a drug discovery platform for women’s reproductive health
The first weeks of human pregnancy are crucial as early abnormalities or insults result in infertility. Therapeutics acting at the onset of embryonic development would offer huge opportunities to improve public health through effe...
The first weeks of human pregnancy are crucial as early abnormalities or insults result in infertility. Therapeutics acting at the onset of embryonic development would offer huge opportunities to improve public health through effective family planning and to reduce an ongoing global fertility decrease with profound economic, social, environmental, and geopolitical consequences. Unfortunately, a drug development program on human embryos is unfeasible due to the inaccessibility and scarcity of embryos, and to ethical issues associated with them. As a result, the attrition rate of drugs for reproductive health is high for all major In Vitro Fertilization (IVF) and pharmaceutical companies.
Recently, an alternative approach arose from stem cells self-organizing into structures closely resembling pre-implantation embryos (blastocysts), which we termed blastoids. Because stem cells can be largely multiplied, this embryo model provides a scalable and ethical alternative amenable to drug screens, thus opening numerous possibilities for therapeutic breakthroughs. Here, I propose to use human blastoids to discover molecules for women’s reproductive health.
Blastoids offer a unique opportunity to establish a drug discovery program for early pregnancy and an alternative to the use of animal and human embryos. As such, this path has the potential to decrease the cost of drug development and to increase the rate of approved drugs for reproductive health. The aim of BLASTOID-DISCOVERY is to investigate the commercial feasibility of using blastoids as a new and highly cost-effective tool in the discovery of therapeutics for reproductive health.
ver más
Duración del proyecto: 18 meses
Fecha Inicio: 2023-10-04
Fecha Fin: 2025-04-30
Fecha Fin: 2025-04-30
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-10-04
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2022-POC2:
ERC PROOF OF CONCEPT GRANTS2
Cerrada
hace 2 años
Presupuesto
El presupuesto total del proyecto asciende a
150K€
Líder del proyecto
INSTITUT FUER MOLEKULARE BIOTECHNOLOGIE GMBH
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5